Literature DB >> 10203609

Primary non-Hodgkin's lymphoma of the female genital tract.

M Amichetti1, E Chiappe, S Mussari, L Busana, O Caffo, F Botto, E Galligioni, L Tomio.   

Abstract

Genital tract lymphoma is a rare disease; information on diagnosis, treatment and outcome are limited. We report on eight patients affected by non-Hodgkin's lymphoma of the genital tract, five from the cervix, two from the vagina and one from the vulva collected between 1987 and 1998. Age at presentation ranged from 36 to 82 (median 67) years. The commonest initial symptom was vaginal bleeding, post coital in 1 patient. Three patients complained of vescical symptoms. Ann Arbor classification was stage IAE for 6 patients. Histology, according to the IWF, was either intermediate grade (4 patients), or high grade (3 patients), not evaluable in one case. Seven patients were treated with chemotherapy (anthracycline based in four) followed by pelvic radiotherapy in five; one patient received irradiation alone. Five patients are currently alive and free of disease with follow-up ranging from 8 to 126 months. Based on our experience in this series, we support a management scheme of combination chemotherapy and radiotherapy for patients with non-Hodgkin's lymphoma of the genital tract.

Entities:  

Mesh:

Year:  1999        PMID: 10203609

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Primary Non-Hodgkin's Lymphoma of the Uterine Cervix: Case Report of Long-Term Survival Patient.

Authors:  N Mouhajir; A Diakité; A Toulba; M Hemmich; I Saadi; H Elkacemi; T Kebdani; N Benjaafar
Journal:  J Obstet Gynaecol India       Date:  2013-12-10

2.  Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases.

Authors:  S Nakamura; M Kato; K Ichimura; Y Yatabe; Y Kagami; R Suzuki; H Taji; E Kondo; S Asakura; M Kojima; S Murakami; K Yamao; T Tsuzuki; G K Adachi; A Miwa; T Yoshidai
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.